Review of clinical practice guidelines for the management of LDL-related risk

Area of Science:

• Cardiology
• Preventive Medicine
• Public Health

Background:

• Low-density lipoprotein (LDL) cholesterol is a key factor in atherogenesis and atherosclerotic cardiovascular disease (ASCVD) risk.
• Despite established therapies, significant gaps exist in patient care, with many not receiving optimal lipid-lowering treatment.
• Confusion surrounding diverse clinical practice guidelines contributes to suboptimal management of LDL-related cardiovascular risk.

Purpose of the Study:

• To review and compare current international guidelines for reducing LDL-related cardiovascular risk.
• To identify variations in guideline development, risk assessment tools, and therapeutic targets.
• To propose strategies for improving consistency and implementation of evidence-based LDL management.

Main Methods:

• Systematic review of major professional society guidelines for LDL cholesterol management.
• Comparative analysis of guideline methodologies, risk assessment strategies, and treatment recommendations.
• Discussion of similarities and differences among US and international guidelines.

Main Results:

• Guidelines exhibit variability in recommendation development, evidence grading, and expert opinion inclusion.
• Discrepancies exist in recommended ASCVD risk assessment tools and lipoprotein targets.
• Significant differences noted between US and international approaches to LDL risk management.

Conclusions:

• Harmonizing international guidelines is essential for consistent LDL risk management.
• Standardizing risk assessment and therapeutic targets can improve evidence-based therapy implementation.
• Addressing guideline variability can help close care gaps and reduce ASCVD events.